Cue Biopharma Stock Price on December 19, 2024

CUE Stock  USD 1.01  0.01  0.98%   
Below is the normalized historical share price chart for Cue Biopharma extending back to January 02, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Cue Biopharma stands at 1.01, as last reported on the 21st of December, with the highest price reaching 1.09 and the lowest price hitting 0.99 during the day.
IPO Date
2nd of January 2018
200 Day MA
1.2694
50 Day MA
1.3122
Beta
1.796
 
Covid
If you're considering investing in Cue Stock, it is important to understand the factors that can impact its price. Cue Biopharma is dangerous given 3 months investment horizon. Cue Biopharma secures Sharpe Ratio (or Efficiency) of 0.15, which signifies that the company had a 0.15% return per unit of standard deviation over the last 3 months. We are able to break down and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.78% are justified by taking the suggested risk. Use Cue Biopharma mean deviation of 7.93, and Risk Adjusted Performance of 0.1091 to evaluate company specific risk that cannot be diversified away.
  
At present, Cue Biopharma's Liabilities And Stockholders Equity is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 24 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 30 M. . As of December 21, 2024, Price To Sales Ratio is expected to decline to 20.90. In addition to that, Price Earnings Ratio is expected to decline to -2.5. Cue Stock price history is provided at the adjusted basis, taking into account all of the recent filings.

Sharpe Ratio = 0.1483

Best PortfolioBest Equity
Good Returns
Average ReturnsCUE
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 12.01
  actual daily
96
96% of assets are less volatile

Expected Return

 1.78
  actual daily
35
65% of assets have higher returns

Risk-Adjusted Return

 0.15
  actual daily
11
89% of assets perform better
Based on monthly moving average Cue Biopharma is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cue Biopharma by adding it to a well-diversified portfolio.
Price Book
2.5599
Enterprise Value Ebitda
(1.76)
Price Sales
7.7135
Shares Float
48.2 M
Wall Street Target Price
3.6

Related Headline

Anixa Biosciences Headline on 19th of December 2024

Key Insights The projected fair value for Anixa Biosciences is US4.21 based on 2 Stage Free Cash Flow to Equity Anixa...

Cue Biopharma Valuation on December 19, 2024

It is possible to determine the worth of Cue Biopharma on a given historical date. On December 19, 2024 Cue was worth 1.1 at the beginning of the trading date compared to the closed value of 1.02. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Cue Biopharma stock. Still, in general, we apply an absolute valuation method to find Cue Biopharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cue Biopharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Cue Biopharma's related companies.
 Open High Low Close Volume
  1.03    1.22    1.01    1.07    453,790  
12/19/2024
  1.10    1.14    1.02    1.02    279,342  
  1.00    1.09    0.99    1.01    624,251  
Backtest Cue Biopharma  |  Cue Biopharma History  |  Cue Biopharma Valuation   PreviousNext  
Open Value
1.1
1.02
Closing Value
37.13
Upside

Cue Biopharma Trading Date Momentum on December 19, 2024

On December 20 2024 Cue Biopharma was traded for  1.01  at the closing time. Highest Cue Biopharma's price during the trading hours was 1.09  and the lowest price during the day was  0.99 . The net volume was 624.3 K. The overall trading history on the 20th of December contributed to the next trading period price depreciation. The overall trading delta to the next next day price was 0.98% . The overall trading delta to current price is 1.96% .

Cue Biopharma Fundamentals Correlations and Trends

By evaluating Cue Biopharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Cue Biopharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Cue financial account trend analysis is a perfect complement when working with valuation or volatility modules.

About Cue Biopharma Stock history

Cue Biopharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Cue is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Cue Biopharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Cue Biopharma stock prices may prove useful in developing a viable investing in Cue Biopharma
Last ReportedProjected for Next Year
Common Stock Shares Outstanding45.8 M30 M
Net Loss-47.7 M-50.1 M

Cue Biopharma Quarterly Net Working Capital

17.44 Million

Cue Biopharma Stock Technical Analysis

Cue Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Cue Biopharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Cue Biopharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Price Boundaries

Cue Biopharma Period Price Range

Low
December 21, 2024
0.00  NaN%
High

 0.00 

     

 0.00 

Cue Biopharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.

Cue Biopharma December 21, 2024 Market Strength

Market strength indicators help investors to evaluate how Cue Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cue Biopharma shares will generate the highest return on investment. By undertsting and applying Cue Biopharma stock market strength indicators, traders can identify Cue Biopharma entry and exit signals to maximize returns

Cue Biopharma Technical and Predictive Indicators

Predictive indicators are helping investors to find signals for Cue Biopharma's price direction in advance. Along with the technical and fundamental analysis of Cue Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Cue to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.

Complementary Tools for Cue Stock analysis

When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Valuation
Check real value of public entities based on technical and fundamental data
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital